Nipro Dialyzer ELISIO-17H: high-flux option for hemodialysis patients

Responsible: ad hoc news Lifestyle & Consumer Desk. Reviewed prior to publication on June 12, 2026 at 3:48 PM ET. Details in the imprint.

Nipro's ELISIO-17H dialyzer is part of the company's high-flux ELISIO family for chronic hemodialysis, aimed at improving solute removal and biocompatibility for patients who depend on treatment several times per week. The single-use device uses a synthetic polysulfone-based hollow-fiber membrane and is offered in multiple surface areas, with the 17H model positioned for adult patients needing approximately 1.7 m² of effective membrane area. In the U.S., Nipro Medical Corporation markets the ELISIO line primarily to dialysis clinics and hospital providers through specialized distributors rather than direct-to-consumer channels. While final pricing depends on supply contracts, the ELISIO-17H is typically purchased by facilities as part of bundled dialysis consumables instead of being sold individually to patients.

How the ELISIO-17H dialyzer is designed to support hemodialysis care

The ELISIO-17H is built around Nipro's ELISIO membrane platform, a synthetic polysulfone-based material engineered to balance high uremic toxin clearance with controlled albumin loss. According to Nipro's product literature, ELISIO dialyzers are designed with a uniform inner diameter hollow-fiber structure and an optimized potting process meant to ensure even blood flow and reduce the risk of stagnation zones. For chronic hemodialysis patients, this type of design is intended to support adequate clearance of small and middle molecules such as urea and beta-2 microglobulin, which are frequently cited targets in dialysis adequacy guidelines. While individual performance metrics vary by prescription and machine settings, high-flux dialyzers like the 17H are commonly used when clinicians aim for greater removal of larger solutes compared with low-flux devices.

Nipro emphasizes the biocompatibility of the ELISIO series, noting features such as a smooth inner surface of the hollow fibers and a sterilization process that aims to limit residuals that could trigger complement activation. Independent clinical literature on hemodialysis membranes indicates that more biocompatible dialyzers are associated with lower inflammatory markers and potentially better long-term outcomes compared with older-generation devices, though results can differ between studies and products. Within that broader context, the ELISIO-17H is positioned as a contemporary high-flux option that aligns with current membrane materials widely used in North American and European dialysis facilities.

In terms of physical specifications, Nipro lists ELISIO dialyzers in a range of sizes from approximately 13 to over 21 in surface area, with the 17H sitting near the middle of the adult portfolio for patients of average body size. The device connects to standard hemodialysis bloodline sets using industry-typical ports and is approved for single-use only, which is in line with U.S. practice where dialyzer reuse has significantly declined compared with past decades. The housing is typically made from medical-grade plastic with integrated blood and dialysate compartments separated by the hollow fiber bundle, and the design aims to minimize hold-up volumes so that priming and blood return are as efficient as possible. For dialysis nurses and technicians, the ELISIO-17H is used much like other high-flux dialyzers on common machine platforms from major manufacturers, which reduces training burden when facilities incorporate Nipro consumables into existing workflows.

Nipro Medical Corporation supplies the ELISIO line throughout the Americas, and the devices are available in the U.S. through medical distributors that specialize in dialysis equipment rather than general consumer marketplaces. Publicly available procurement references and catalog listings indicate that ELISIO dialyzers, including the 17H model, are ordered in bulk by outpatient dialysis chains, independent centers, and hospital-based units. For patients, the cost of the dialyzer is bundled into the overall hemodialysis treatment charge, which in the U.S. is generally reimbursed under Medicare's end-stage renal disease (ESRD) prospective payment system or commercial insurance arrangements. Because of this bundled model, a consumer-style MSRP in U.S. dollars is not typically posted by the manufacturer for the ELISIO-17H, and pricing often reflects contract terms between Nipro and provider organizations.

From a regulatory perspective, Nipro's dialyzers are cleared in the U.S. as Class II medical devices via the 510(k) pathway, with substantial equivalence claimed to predicate hemodialyzer devices already on the market. The company notes that ELISIO products are gamma sterilized and packed for single-patient use, with instructions for use specifying contraindications such as known hypersensitivity to any component materials. Clinicians remain responsible for selecting an appropriate dialyzer based on patient size, vascular access, and treatment goals, and the ELISIO-17H provides one option among multiple high-flux dialyzers available from different manufacturers. For dialysis providers evaluating consumable lines, factors such as clearance performance, fiber material, perceived biocompatibility profile, and supply chain reliability are often weighed alongside cost.

For Nipro, the ELISIO dialyzer family complements its broader renal portfolio, which includes blood tubing sets, fistula needles, catheters, and dialysis machines marketed in select regions. The company positions itself as a full-line supplier to dialysis centers, particularly in Asia and Latin America, while competing with other global manufacturers in the U.S. consumables market. Shares of Nipro (JP3563400006, ticker NPROY) traded at $10.28 on the OTC market on June 11, 2026.

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.